Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project

COLLEGE STATION, TX / ACCESSWIRE / June 26, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, today provided an update regarding Virogentics, Inc.'s ("VIRO") ITV-1 African Project.

The final protocol for the administration of the ITV-1 immunotherapy treatment under the supervision of Neuro Pharma Ltd - Rwanda, to be dispensed to volunteers under a fast-track protocol at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC, has been completed and delivered to the DRC Ministry of Health Department of HIV and Aids for final approval. The vials with the necessary informational inserts are awaiting the approval of the final protocol report for distribution. The impact of the treatment on the HIV/AIDS virus present in the volunteers will be reported after the 17-week cycle is complete. The next step for VIRO is to acquire and fund the insurance premiums for the volunteers. VIRO expects ITV-1 to be dispensed under the trial in late July / early August 2023.

VIRO has also recently submitted an application with GNC for IPF Immune to be sold on-line. VIRO continues to sell out of the inventory shipped to Amazon and WalMart. VIRO expects to be able to increase production in the near future to meet the growing market demand for this FDA registered nutraceutical.

Harry Zhabiov, CSO of VIRO stated, " As we count down the days to the initial injections in victims of HIV/Aids in African patients we feel confident that all the hard work and support we have received over the 15 year journey will soon be rewarded".

Enzolytics, Inc. Overview

Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.